Raymond Wadlow, MD

Raymond Wadlow, MD, a medical oncologist at Virginia Cancer Specialists, discusses results from the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer (CRC).

During a presentation at the 2019 Gastrointestinal Cancers Symposium, an overall survival benefit of approximately 2.5 months was found in patients with microsatellite-stable CRC.

This is exciting as it is the first finding, according to Wadlow, that shows a statistically significant improvement with a checkpoint inhibitor in the majority of this patient population.

See more from the 2019 Gastrointestinal Cancers Symposium.

Videos

Raymond Wadlow, MD, discusses the results for the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer.

Investigating Immunotherapy Versus Best Supportive Care in Patients With CRC

Raymond Wadlow, MD, a medical oncologist at Virginia Cancer Specialists, discusses interesting data presented for hepatocellular carcinoma (HCC) at the 2018 Gastrointestinal Cancers Symposium.

One analysis looked at the role of neoadjuvant immunotherapy in patients with resectable HCC. While this is a small subset of patients, Wadlow says that 3 of the 8 patients had pathologic complete responses, 2 with a checkpoint combination and 1 with a single-agent PD-L1 inhibitor.

Raymond Wadlow, MD, discusses interesting data presented for hepatocellular carcinoma at the 2018 Gastrointestinal Cancers Symposium.

Raymond Wadlow, MD | Authors

Articles

Investigating Immunotherapy Versus Best Supportive Care in Patients With CRC

Data Suggest Potential for Immunotherapy in HCC